home / stock / orinf / orinf quote
Last: | $47.16 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $47.16 |
High: | $0 |
Low: | $0 |
Volume: | 2,695 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$47.16 | $0 | $47.16 | $0 | $0 | 2,695 | 04-24-2024 |
$47.16 | $0 | $47.16 | $0 | $0 | 154 | 03-28-2024 |
$47.16 | $0 | $47.16 | $0 | $0 | 10 | 03-14-2024 |
$47.16 | $0 | $47.16 | $0 | $0 | 5 | 02-28-2024 |
$47.16 | $0 | $47.16 | $0 | $0 | 43 | 01-31-2024 |
$47.16 | $47.16 | $47.16 | $47.16 | $47.16 | 629 | 01-25-2024 |
$38.381 | $0 | $38.381 | $0 | $0 | 1,563 | 12-14-2023 |
$38.381 | $0 | $38.381 | $0 | $0 | 6 | 10-03-2023 |
$38.381 | $38.381 | $38.381 | $38.381 | $38.381 | 1,509 | 09-28-2023 |
$37.44 | $38.19 | $37.44 | $38.19 | $37.44 | 2,744 | 09-22-2023 |
$37 | $0 | $37 | $0 | $0 | 248 | 09-12-2023 |
$37 | $37 | $37 | $37 | $37 | 758 | 08-23-2023 |
$46 | $0 | $46 | $0 | $0 | 10 | 07-21-2023 |
$46 | $0 | $46 | $0 | $0 | 1,346 | 07-13-2023 |
$46 | $0 | $46 | $0 | $0 | 139 | 07-12-2023 |
$46 | $0 | $46 | $0 | $0 | 6 | 07-10-2023 |
$46 | $0 | $46 | $0 | $0 | 110 | 06-13-2023 |
$46 | $0 | $46 | $0 | $0 | 372 | 06-09-2023 |
$46 | $46 | $46 | $46 | $46 | 100 | 05-15-2023 |
$46.65 | $0 | $46.65 | $0 | $0 | 172 | 05-11-2023 |
News, Short Squeeze, Breakout and More Instantly...
Orion Corp New B Shs Company Name:
ORINF Stock Symbol:
OTCMKTS Market:
ORION CORPORATION PRESS RELEASE 26 JANUARY 2024 at 09.00 EET Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024 Orion presented yesterday at the 2024 ASCO GU Cancers Symposium a poster with additional data from the ongoing Phase II CYPIDES trial evaluating the safety...
ORION CORPORATION PRESS RELEASE 8 JANUARY 2024 at 09.00 EET Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs Orion Corporation and Glykos Finland Oy announced today that they have entered into a research collaborat...
ORION CORPORATION PRESS RELEASE 05 JANUARY 2023 at 13:45 EET Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patients with Metastatic Castration-Resistant Prostate Cancer OMAHA1 and OMAHA2a are the first Phase 3 trials to be initiated for...